Pancreatic Duct Evaluation in Autoimmune Pancreatitis: MR Pancreatography

Sponsor
Jae Ho Byun (Other)
Overall Status
Completed
CT.gov ID
NCT01773031
Collaborator
Guerbet (Industry)
30
1
25.9
1.2

Study Details

Study Description

Brief Summary

A prospective intra-individual study to compare the image quality of magnetic resonance (MR) pancreatography at 3.0 T and 1.5 T in patients with autoimmune pancreatitis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Autoimmune pancreatitis (AIP) is a unique form of chronic pancreatitis caused by an autoimmune mechanism that responds well to steroid therapy. One of the most important issues on AIP is to distinguish it from pancreatic cancer as the treatments are totally different from each other. An accurate differentiation of AIP from pancreatic cancer is therefore crucial.

    Two most important image findings of AIP are pancreatic enlargement and pancreatic ductal stricture. When CT shows typical diffuse sausage-like swelling of the pancreas and peripancreatic hypodense rim, it is easy to differentiate AIP from pancreatic cancer. However, those typical cases are not very common and, moreover, 30% of AIP manifest as focal mass/enlargement of the pancreas, making a differential diagnosis very difficult. When pancreatic feature is atypical at CT, it is important to find diffuse or multifocal stricture of the main pancreatic duct that is characteristic feature of AIP. In AIP, a diffusely attenuated pancreatic duct is thinner than normal, and this does not appear at CT. Pancreatography is therefore necessary.

    Two current imaging tools to demonstrate the pancreatic duct are endoscopic retrograde pancreatography (ERP) and MR pancreatography (MRP). ERP provides high resolution images using different projections and enables various procedures including aspiration/biopsy and stent insertion. However, the use of diagnostic ERP in diagnosing AIP has been debated as ERP is an invasive procedure, having potential complications including pancreatitis, perforation of the stomach or duodenum. Moreover, it is difficult to perform endoscopic procedure in patients who underwent gastric surgery. Whereas, MRP can noninvasively image the pancreatic and biliary systems at the same time without risks of procedure-related complications and can evaluate other intrabdominal organs on cross-sectional images. The relatively lower spatial resolution of MRP using 1.5 T compared with ERP images may make it difficult to demonstrate fine changes of the pancreatic duct in AIP and sometimes make false positive or negative findings.

    The superiority of 3.0 T over 1.5 T MR systems has been observed in several studies. However, only a few studies using the 3.0 T MR systems in the pancreaticobiliary tract have been reported and, furthermore, the usefulness of 3.0 T MRP for the diagnosis of AIP has not yet been investigated.

    The purpose of this study is to prospectively compare the image quality of MRP at 3.0 T and 1.5 T in patients with AIP using ERP as the reference standard.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    30 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    Pancreatic Duct Evaluation in Autoimmune Pancreatitis: Intraindividual Comparison of MR Pancreatography at 3.0 T and 1.5 T
    Study Start Date :
    Jan 1, 2013
    Actual Primary Completion Date :
    Mar 1, 2015
    Actual Study Completion Date :
    Mar 1, 2015

    Arms and Interventions

    Arm Intervention/Treatment
    Autoimmune pancreatitis

    Patients with autoimmune pancreatitis based on clinical and CT findings

    Outcome Measures

    Primary Outcome Measures

    1. Scoring for visualization of the main pancreatic duct on 1.5 T and 3.0 T MRP [Outcome measure will be assessed after a week following MRP examination]

      Scoring for overall visualization of the main pancreatic duct (MPD): 1-4 points (1, entirely invisible; 2, faintly and partially visible; 3, faintly but entirely visible/clearly but partially visible; 4, clearly and entirely visible) Scoring for visualization of MPD stricture: 1-4 points (1, invisible; 2, poorly visible; 3, moderately visible; 4, clearly visible) Reference standard: ERP

    Secondary Outcome Measures

    1. Signal-to-noise ratio of the main pancreatic duct on 1.5 T and 3.0 T MRP [Outcome measure will be assessed after a week following MRP examination]

    2. The rate of concordance in the stricture type of the main pancreatic duct between MRP and ERP [Outcome measure will be assessed after a week following MRP examination]

      Stricture type of the main pancreatic duct: 1, diffuse; 2, segmental; 3, focal; 4, multifocal

    3. Scoring for confidence in diagnosing AIP based on MRP findings [Outcome measure will be assessed after a week following MRP examination]

      Scoring for confidence: 1-4 points (1, low probability; 2, indeterminate probability; 3, moderate probability; 4, high probability)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Typical CT findings (diffuse sausage-like pancreatic swelling or multifocal pancreatic swelling with or without peripancreatic rim, multifocal biliary stricture, renal lesion, or retroperitoneal fibrosis)

    • Serum level of immunoglobulin G fraction 4 > 135mg/dL

    Exclusion Criteria:
    • Patients under 20 years of age

    • Women who are pregnant, lactating or who are of childbearing potential

    • Patients with any physical or mental status that interferes with the signing of informed consent

    • Patients with a contraindication for MRP or ERP examination

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Division of Abdomen, Department of Radiology & Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center Seoul Korea, Republic of 138-736

    Sponsors and Collaborators

    • Jae Ho Byun
    • Guerbet

    Investigators

    • Principal Investigator: Jae Ho Byun, MD, PhD, University of Ulsan College of Medicine, Asan Medical Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Jae Ho Byun, Associate Professor, Asan Medical Center
    ClinicalTrials.gov Identifier:
    NCT01773031
    Other Study ID Numbers:
    • AMC-2012-1756
    First Posted:
    Jan 23, 2013
    Last Update Posted:
    Dec 30, 2015
    Last Verified:
    Dec 1, 2015
    Keywords provided by Jae Ho Byun, Associate Professor, Asan Medical Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 30, 2015